• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Herpes zoster subunit vaccine may be more cost-effective than live attenuated zoster vaccine

byShayna BejaimalandAnees Daud
January 5, 2018
in Chronic Disease, Dermatology, Emergency, Infectious Disease, Neurology, Oncology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The new adjuvanted herpes zoster subunit vaccine was more efficacious and less expensive for all ages at the price of $280 per series as compared to the single-dose herpes zoster vaccine.

2. It is unclear if a booster of the live attenuated herpes zoster vaccine would be cost-effective, as this was not investigated in this study.

Evidence Rating Level: 2 (Good)

Study Rundown: It is recommended that immunocompetent adults 60 years or older get the live attenuated herpes zoster vaccine (ZVL), however its efficacy decreases over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) may have higher efficacy over time but may be more expensive. This study aimed to assess the cost-effectiveness of the HZ/su vaccine as compared to the ZVL vaccine.

The HZ/Su vaccine was more effective and less expensive than ZVL vaccine for all ages at a price of $280 ($140 per dose for two doses). The HZ/su vaccine had a 73% probability of being cost-effective for 60-year-olds at $50,000 per quality-adjusted life-year (QALY). Limitations of this study include unknown adherence to the second dose of HZ/su. This study did not look at the possibility of a ZVL booster and thus this could be subject for further study.

Click to read the study, published in JAMA Internal Medicine

Relevant Reading: Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis

RELATED REPORTS

BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

BNT162b2 booster dose associated with reduced risk of SARS-CoV-2 infection and mortality among older adults in long-term care facilities

In-Depth [decision model]: This Markov decision modeling study was conducted in July 2017 using randomized clinical trial data from medical literature search and aimed to compare the cost-effectiveness of no vaccination, vaccination with ZVL (1 dose) and vaccination with HZ/su (2 doses). Analyses were conducted separately for people aged 60-69, 70-79 and 80 years old and onwards. This was done because the cost-effectiveness of ZVL vaccines varies by vaccination age. Data was derived from participant groups ranging in number from less than 100 to more than 30,000 depending on the variable assessed. The main outcome of interest was total costs and estimated QALYs. Deterministic and probabilistic sensitivity analyses were conducted.

A price of $280 per two-dose series ($140 per dose) of the HZ/su vaccine was more effective and less expensive than the ZVL vaccine at all ages. At all ages no vaccination was the least expensive and least effective. The HZ/su was highly cost-effective compared with no vaccination with an incremental cost-effectiveness ratio below $50,000 per QALY at all ages. The finding was insensitive to variations in most model inputs other than vaccine price and adherence rate. In probabilistic sensitivity analysis HZ/su had 73% probability of being cost-effective for 60-year-olds at $50,000 per QALY.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Shingles (Herpes Zoster)vaccinationvaccine
Previous Post

Microcephaly rates elevated in Brazil prior to Zika virus epidemic

Next Post

Autologous stem-cell transplantation improves survival in scleroderma patients: The SCOT trial

RelatedReports

Infectious Disease

BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children

August 18, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

July 26, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

BNT162b2 booster dose associated with reduced risk of SARS-CoV-2 infection and mortality among older adults in long-term care facilities

July 8, 2022
Lower vulvar cancer-related mortality in African Americans
Infectious Disease

Hybrid immunity protects against infection with omicron variant of COVID-19

July 7, 2022
Next Post
Palliative care intervention improves quality of life during hospitalization for hematopoietic stem cell transplantation

Autologous stem-cell transplantation improves survival in scleroderma patients: The SCOT trial

Nonpowder gun-related pediatric eye injuries on the rise

Nonpowder gun-related pediatric eye injuries on the rise

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

2 Minute Medicine Rewind January 8, 2018

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
  • #VisualAbstract: Stenting in addition to medical therapy does not reduce stroke or mortality risk in patients with severe intracranial stenosis
  • Percutaneous radiofrequency ablation effective in small, exophytic renal cell carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.